1. Home
  2. ADX vs AGIO Comparison

ADX vs AGIO Comparison

Compare ADX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADX
  • AGIO
  • Stock Information
  • Founded
  • ADX 1840
  • AGIO 2007
  • Country
  • ADX United States
  • AGIO United States
  • Employees
  • ADX N/A
  • AGIO N/A
  • Industry
  • ADX Investment Managers
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADX Finance
  • AGIO Health Care
  • Exchange
  • ADX Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • ADX 2.3B
  • AGIO 2.3B
  • IPO Year
  • ADX N/A
  • AGIO 2013
  • Fundamental
  • Price
  • ADX $21.78
  • AGIO $36.55
  • Analyst Decision
  • ADX
  • AGIO Buy
  • Analyst Count
  • ADX 0
  • AGIO 6
  • Target Price
  • ADX N/A
  • AGIO $57.00
  • AVG Volume (30 Days)
  • ADX 182.4K
  • AGIO 652.4K
  • Earning Date
  • ADX 01-01-0001
  • AGIO 10-30-2025
  • Dividend Yield
  • ADX 6.68%
  • AGIO N/A
  • EPS Growth
  • ADX N/A
  • AGIO N/A
  • EPS
  • ADX N/A
  • AGIO 11.13
  • Revenue
  • ADX N/A
  • AGIO $40,875,000.00
  • Revenue This Year
  • ADX N/A
  • AGIO $28.19
  • Revenue Next Year
  • ADX N/A
  • AGIO $152.14
  • P/E Ratio
  • ADX N/A
  • AGIO $3.25
  • Revenue Growth
  • ADX N/A
  • AGIO 30.57
  • 52 Week Low
  • ADX $14.94
  • AGIO $23.42
  • 52 Week High
  • ADX $19.57
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • ADX 52.53
  • AGIO 46.91
  • Support Level
  • ADX $21.43
  • AGIO $32.70
  • Resistance Level
  • ADX $21.89
  • AGIO $41.10
  • Average True Range (ATR)
  • ADX 0.25
  • AGIO 1.78
  • MACD
  • ADX -0.01
  • AGIO -0.08
  • Stochastic Oscillator
  • ADX 63.61
  • AGIO 47.08

About ADX Adams Diversified Equity Fund Inc.

Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: